TRiMM-2: Talquetamab + Daratumumab in Relapsed/Refractory Multiple Myeloma
In the context of other clinical trials for patients with relapsed/refractory multiple myeloma, Ajai Chari, MD, and Carolina Schinke, MD, review data from TRiMM-2.
Key Takeaways From RedirecTT-1: Teclistamab + Talquetamab in Relapsed/Refractory MM
Expert perspectives on the real-world use of combination teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.
Relapsed/Refractory MM: Safety and Efficacy Data From RedirecTT-1
Centering discussion on RedirecTT-1, expert hematologist-oncologists consider safety and efficacy data with the combination of teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.
Relapsed/Refractory Multiple Myeloma: Sequencing BCMA-Targeting Therapies
Shared perspective on available novel therapies in relapsed/refractory multiple myeloma and how best to sequence these agents.
Long-Term Followup With Talquetamab in Relapsed/Refractory MM: Infection Rates
Expert hematologist-oncologists identify long-term data from MonumenTAL-1 regarding infection rates in patients with relapsed/refractory multiple myeloma.
Practical Considerations for Talquetamab Use in Relapsed/Refractory Multiple Myeloma
Following their review of data from MonumenTAL-1, Ajai Chari, MD, and Carolina Schinke, MD, share practical considerations for real-world use of talquetamab in relapsed/refractory multiple myeloma.
Relapsed/Refractory MM: Safety and Efficacy Data From MonumenTAL-1
Focused discussion on the safety and efficacy data from MonumenTAL-1, which utilized talquetamab monotherapy in patients with relapsed/refractory multiple myeloma.
MonumenTAL-1 in Relapsed/Refractory MM: Overview of Study Design
Following a brief review of the relapsed/refractory multiple myeloma treatment landscape, Carolina Schinke, MD, provides an overview of the MonumenTAL-1 study design.
Educating Patients and Caregivers on Infection Risks of Anti-BCMA Bispecific Antibodies in MM Treatment
The panel discusses how to educate patients and caregivers on infections risks when receiving an anti-BCMA bispecific antibody.
Viral Infections in Patients With MM Treated with Anti-BCMA Bispecific Antibodies
Robert Mancini, PharmD, explains the viral infections commonly seen in multiple myeloma patients treated with anti-BCMA bispecific antibodies.
Bacterial Infections in Patients With MM Treated with Anti-BCMA Bispecific Antibodies
Dr Robert Mancini details the bacterial infections usually seen in multiple myeloma patients treated with anti-BCMA bispecific antibodies.
Data on Infections and Severe Hypogammaglobulinemia in MM Patients Treated with Anti-BCMA Bispecific Antibodies
Dr Ajai Chari reviews data from a study looking at the rates of infection in patients with multiple myeloma treated with BCMA-targeting bispecific antibodies, including severe hypogammaglobulinemia.
Clinical Pearls on CRS and ICANS Management in Multiple Myeloma
Moderator Ajai Chari, MD, leads the panel in sharing clinical pearls for management of CRS and ICANS in multiple myeloma before closing out the final module.
Educating Infusion Nurses on Infection Risks of Anti-BCMA Bispecific Antibodies in MM Treatment
Experts discuss how they educate infusion nurses and other colleagues treating patients with multiple myeloma on the infection risks of BCMA-targeting bispecific antibodies.
Patient Case 3: Development of CRS on a Non-BCMA Targeted Bispecific Antibody
Centering discussion on the third patient case of multiple myeloma, key opinion leaders consider the development of CRS on non-BCMA targeted bispecific antibody therapy.
Patient Case 3: A 79-Year-Old Female With IgG Kappa Multiple Myeloma
Registered Nurse Annel Urena presents the case of a 79-year-old female with IgG Kappa multiple myeloma and five previous lines of therapy.
Management of ICANS Associated with Bispecific Antibodies in MM
A brief review of available management strategies used in practice when patients with multiple myeloma develop immune effector cell-associated neurotoxicity syndrome.
Patient Case 2: A 74-Year-Old Male With Kappa LC Multiple Myeloma
Nurse Practitioner Kiah Purcell presents a case of a 74-year-old male with kappa light chain myeloma after ten lines of therapy.
Patient Case 2: Development of ICANS on a BCMA-Targeted Bispecific Antibody
Switching focus to the second patient case of multiple myeloma, panelists reflect on the prevalence and impact of ICANS on patients being treated with bispecific antibodies.
Cytokine Release Syndrome Grading and Management Strategies in MM
Comprehensive insight on the grading system for cytokine release syndrome and available treatment strategies utilized in practice when patients with multiple myeloma develop CRS.
Patient Case 1: A 69-Year-Old Male With Relapse/Refractory IgG Lambda Multiple Myeloma
Annel Urena, RN, BSN, presents the case of a 69-year-old male with relapsed refractory IgG Lambda multiple myeloma after six lines of therapy.
Infection Patterns of Bispecific Antibodies in Multiple Myeloma Treatment
Robert Mancini, PharmD, and Kiah Purcell, AGPCNP-B, discuss other targets for bispecific antibodies in multiple myeloma treatment and the infection patterns.
Administering Step-up and Treatment Doses of Bispecifics in MM
A brief review of bispecific antibody dosing strategies in multiple myeloma to improve patient outcomes and address concurrent adverse events.
Overview of Bispecific Antibodies in Multiple Myeloma Treatment
Dr Robert Mancini summarizes the role of BCMA-targeted bispecific antibodies in multiple myeloma treatment and the side effects usually seen.
Patient Case 1: Development of CRS on a BCMA-Targeted Bispecific Antibody
Expert panelists review the first patient case of multiple myeloma wherein cytokine release syndrome (CRS) develops during treatment with a BCMA-targeted bispecific antibody.
Role of Multidisciplinary Care in With MM Receiving Bispecific Antibodies
Shared insight on the respective roles of a multidisciplinary care team involved in the management of multiple myeloma and associated adverse events.
Multiple Myeloma: Role of Bispecifics in an Evolving Treatment Landscape
Advice for Patients, Nurse Practitioners, and Community Oncologists on Teclistamab Therapy in Multiple Myeloma
The panel shares closing advice for patients with multiple myeloma receiving teclistamab, and community providers and nurse practitioners administering teclistamab to patients.
CAR T-Cell Therapy in Multiple Myeloma and Quality of Life
A look at the quality of life of patients with multiple myeloma who received CAR T-cell therapy.
Counseling Patients with Multiple Myeloma on the Infection Risks of BCMA-Targeting Bispecifics
The panel continues their discussion on infection risk with a look at the immunosuppressive effects of BCMA-targeting bispecifics.
2 Clarke Drive Cranbury, NJ 08512